NCT02271906 2019-04-30The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant SettingM.D. Anderson Cancer CenterPhase 2 Terminated2 enrolled 8 charts
NCT01121393 2018-12-14BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)Boehringer IngelheimPhase 3 Completed364 enrolled 28 charts 1 FDA
NCT00949650 2018-04-06BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationBoehringer IngelheimPhase 3 Completed345 enrolled 23 charts 1 FDA